Annual report pursuant to Section 13 and 15(d)

Liquidity (Details Narrative)

v3.8.0.1
Liquidity (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Accumulated deficit $ 65,698,101 $ 33,276,489  
Proceeds from sale of stock 78,891,699 16,699,133 $ 11,328,929
Cash on hand 62,537,495 $ 14,992,257  
2018 CFF Award [Member]      
Amount received for development award 6,250,000    
Sales Agreement [Member]      
Proceeds from sale of stock 13,724,591    
Sales Agreement [Member] | January 2018 [Member]      
Proceeds from sale of stock 11,300,000    
Investment Agreement [Member] | January 26, 2018 [Member] | Phase 2b Clinical Trial [Member]      
Amount received for development award 6,250,000    
Cantor Fitzgerald & Co. [Member] | Sales Agreement [Member] | January 5, 2018 [Member]      
Number of common stock value sold $ 50,000,000    
Number of common stock share sold 1,500,000    
Proceeds from sale of stock $ 11,300,000